Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with revenues of ₹80,705 million, gross profit of ₹37,540 million, and a net profit of ₹4,348 million. The company has also announced the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, and the appointment of M/s Deloitte Haskins & Sells, LLP as the Independent Registered Public Accounting Firm.

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited has informed the Exchange about Conference call Transcript regarding Semaglutide Update Call. The company has scaled up the synthetic API manufacturing process, but one of the impurities was found to be out of specifications. A thorough investigation is underway to determine the root cause and implement necessary process improvements.

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited has announced the release of Q1FY27 results on July 22nd, 2026, after the Board Meeting, along with an earnings call at 19:30 PM IST / 10:00 AM ET.

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited has made available the audio recording of its conference call held on July 9, 2026, as per SEBI regulations.

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited has informed the Exchange about an issue with certain batches of semaglutide due to an active pharmaceutical ingredient (API) issue, which will delay commercial supplies until the issue is resolved. The company is investigating the root cause and taking measures to ensure product quality.

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited has announced that certain batches of semaglutide were found to be out of specification due to an issue with the active pharmaceutical ingredient (API) used in the product, leading to commercial supply delays. The company is investigating the root cause and taking measures to ensure product quality. There is no impact on patient safety or existing regulatory filings.

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities and listing on the stock exchange.

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited has informed the Exchange about a copy of newspaper publication regarding notice of 42nd Annual General Meeting and e-Voting information.

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited has informed the Exchange regarding 'Letter to shareholders in relation to Integrated Annual Report of the Company for FY 2025-26'. The company has announced the 42nd Annual General Meeting (AGM) to be held on July 23, 2026, through Video Conferencing (VC)/Other Audio Visual Means (OAVM). The Notice and Integrated Annual Report for Financial Year 2025-26 is available for download from the company's website. The company has also declared a final dividend of ₹8 per equity share, with a record date of July 10, 2026, and a payment date of July 30, 2026.

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited has informed the Exchange about Integrated Annual Report FY 2026, in compliance with the Companies Act, 2013 and SEBI Listing Regulations.

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited has released its Business Responsibility and Sustainability Report for FY 2025-26, highlighting various initiatives and achievements in areas such as employee training, sustainability, and stakeholder engagement.

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited has informed the Exchange regarding Notice of 42nd Annual General Meeting to be held on July 23, 2026, to consider and pass various resolutions including re-appointment of a director, appointment of statutory auditors, and declaration of final dividend.

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited has informed the Exchange about a Pre-License Inspection (PLI) at its biologics manufacturing facility in Bachupally, Hyderabad, by the United States Food & Drug Administration (USFDA). The inspection was conducted between June 16 and June 25, 2026, and a Form 483 with seven observations was issued. The company will address the observations within the stipulated timeline.

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited announced a Board meeting on July 22, 2026, to consider its Un-audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. In accordance with SEBI regulations, the trading window for dealing in the company's securities will be closed from June 24, 2026, to July 24, 2026. This routine intimation ensures compliance and prevents insider trading prior to the financial results disclosure.

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited has announced the publication of newspaper advertisements concerning its upcoming 42nd Annual General Meeting (AGM). These advertisements provide the official notice for the AGM, which will be conducted through video conference. Crucially for shareholders, the notice also includes information regarding the record date and the final dividend proposed by the company. This announcement is significant for investors, providing key details for determining dividend eligibility and participating in the annual meeting.

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited announced the allotment of 6,730 fully paid-up equity shares, each with a face value of Re.1/-. These shares were issued on June 19, 2026, to eligible employees who exercised their stock options under the company's ESOP Schemes from 2002 and 2007. This routine event reflects the company's commitment to employee incentive and retention programs. For investors, this results in a minor increase in the total outstanding shares, leading to a negligible dilution of existing equity.